Aptevo + Niowave: 50/50 radiopharma collaboration with strategic equity investment
What's the deal? Aptevo TherapeuticsDealroom has a profile for this one. Try Dealroom → and NiowaveDealroom has a profile for this one. Try Dealroom → have launched a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programmes. Niowave made an at-the-market equity investment in Aptevo at closing, taking an initial 7.9% ownership stake with the potential to build up to 19.99% through warrant exercises and future stock purchases.
The deal pairs Aptevo's multispecific antibody platforms — ADAPTIR and ADAPTIR-FLEX — with Niowave's radioisotope production and supply capabilities, including Actinium-225. The first programme will target Nectin-4, a clinically validated cancer target with broad relevance across solid tumours.
Aptevo is a Nasdaq-listed, clinical-stage biotech based in Seattle. Niowave, headquartered in Lansing, Michigan, is a radioisotope production specialist with established partnerships across the radiopharmaceutical ecosystem.
Why now? Radiopharmaceuticals — therapies that deliver radioactive payloads directly to tumours — have emerged as one of oncology's fastest-growing areas. Big pharma has poured billions into the space, and supply of key isotopes like Actinium-225 remains constrained. For Niowave, investing in a therapeutic development programme for the first time signals confidence that its manufacturing edge can translate into clinical-stage value. For Aptevo, it opens a new application for its targeting technology beyond its existing immuno-oncology pipeline.
What could go wrong? Radiopharmaceutical development is technically complex, and neither company has brought a product in this class to market. Aptevo remains a clinical-stage company, meaning cash runway and execution risk are ever-present concerns. The isotope supply chain, while a potential advantage for the partnership given Niowave's capabilities, remains a broader industry bottleneck that could slow development timelines.
The equity structure — with Niowave's stake starting at 7.9% and potentially growing to nearly 20% — aligns incentives but also introduces dilution for existing Aptevo shareholders.
The signal: Both Aptevo and Niowave are classified as "breakout" stage companies on Dealroom, underscoring that this is a bet between two smaller players looking to punch above their weight in a sector increasingly dominated by big pharma acquisitions. The partnership's real leverage lies in Niowave's isotope supply capabilities at a time when Actinium-225 scarcity is a binding constraint across the radiopharmaceutical industry — making manufacturing access as strategically valuable as the targeting science itself.
Read more: MarketScreener
